individuals exhibited broader cross-neutralizing responses than those w/hybrid immunity, suggesting that infection history may narrow antibody responses through immune imprinting. These findings highlight the ongoing challenge of maintaining vaccine effectiveness against evolving SARS-CoV-2 variants